Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will Keytruda Price Differential Really Count In India?

Executive Summary

Merck has launched Keytruda at an “India-specific” price but some experts say that the immuno-oncology therapy will likely still be beyond the reach of a majority of patients. Merck though also expects to offer a patient access program for those who can’t afford the therapy.

You may also be interested in...



AstraZeneca's Imfinzi, Lynparza On Track To India Debut

AstraZeneca, which recently committed to scaling up investments in India, appears on course to bringing two key new anticancers to the country, including the PD-1/L1 inhibitor Imfinzi. Pricing aspects for the products in what is a largely out-of-pocket market are, however, expected to be decisive.

Keytruda’s Catch-22 Situation In India Amid Compliance Questions

Merck & Co’s immuno-oncology therapy Keytruda appears be facing a rather paradoxical situation in India, after an expert panel noted that the US multinational had failed to comply with Phase IV study requirements pertaining to the product in the country.

New Melanoma Frontier Opens To Bristol's Opdivo And Novartis/Glaxo's BRAF/MEK Combo

Bristol's Opdivo and Novartis/GlaxoSmithKline's Tafinlar/Mekinist combo both performed well in early, post-surgical treatment of advanced melanoma in trials reported at ESMO, promising yet another revolution in the standard of care, but leaving Roche's Zelboraf/Cotellic in the dust.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099481

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel